Neuroprotection Devices Market Summary
The Neuroprotection Devices Market is growing at a CAGR of 6.87% during the forecast period from 2025 to 2032. The demand for neuroprotection devices is being driven by the increasing prevalence of cardiovascular and neurovascular disorders, along with growing awareness of the associated risks during medical procedures. Additionally, heightened product development efforts by key market players are contributing to market expansion.
Explore DelveInsight’s Full Coverage on the Neuroprotection Devices Market
Neuroprotection Devices Overview
The Neuroprotection Devices Market encompasses a broad range of medical technologies designed to prevent or minimize neurological damage during cardiovascular and neurovascular interventions. These devices are used across a spectrum of procedures where the risk of embolic events, brain injury, or neurological deterioration is significantly elevated.
The market is segmented by product type into Cerebral Embolic Protection Devices, Therapeutic Hypothermia Devices, Neuroprotective Drug Delivery Devices, and Others. By application, the market covers Cardiovascular Diseases and Neurovascular Diseases, while end-users include Hospitals, Specialty Clinics, and Others. Geographically, the market spans North America, Europe, Asia-Pacific, and Rest of the World.
Neuroprotection Devices Market Trends & Insights
The Neuroprotection Devices Market is estimated to grow at a CAGR of 6.87% during the forecast period from 2025 to 2032. These factors are expected to support steady and robust growth in the neuroprotection devices market from 2025 to 2032. North America is expected to hold the largest share of the Neuroprotection Devices Market in 2024, primarily due to the rising number of cardiovascular and neurovascular interventions. The fastest-growing market during the forecast period is Asia-Pacific.
In the product type segment, the cerebral embolic protection devices category is estimated to account for the largest market share in 2024. The growth of this category is primarily driven by the rising prevalence of cardiovascular and neurovascular diseases, along with the various advantages these devices offer in neuroprotection.
Neuroprotection Devices Market Players
Key companies operating in the Neuroprotection Devices market landscape include:
- Medtronic
- Boston Scientific Corporation
- Abbott Laboratories
- NeuroPace, Inc.
- BD
- Asahi Kasei Corporation
- NeuroSigma, Inc.
- Venus Medtech (Hangzhou) Inc.
- Rheos Medical Corp.
- Baxter
- Aleva Neurotherapeutics
- Renishaw plc.
- Belmont Medical Technologies
- BrainCool AB
- Contego Medical, Inc.
- Integer Holdings Corporation
- InspireMD Inc.
- Emboline, Inc.
- Keystone Heart Ltd.
- Lepu Medical Technology (Beijing) Co., Ltd.
- And Others.
Neuroprotection Devices Market Size and Forecasts
The Neuroprotection Devices Market is projected to grow at a CAGR of 6.87% during the forecast period from 2025 to 2032. Key market sizing parameters are as follows:
- Growth Rate (2025–2032): 6.87% CAGR
- Largest Neuroprotection Devices Market: North America
- Fastest Growing Market: Asia-Pacific
Factors Contributing to the Neuroprotection Devices Market Growth
Rising Prevalence of Neurological Disorders
The increasing global burden of neurological diseases such as ischemic stroke, traumatic brain injuries, and aneurysms is one of the strongest drivers for the neuroprotection devices market. With stroke alone ranking as a leading cause of disability and mortality worldwide, the demand for advanced neuroprotection solutions to prevent secondary brain damage continues to grow.
Growing Aging Population
The expanding elderly population is highly vulnerable to cerebrovascular diseases and neurodegenerative conditions. As the risk of stroke, Alzheimer’s disease, and other neurological disorders escalates with age, the adoption of neuroprotection devices becomes increasingly essential, thereby fueling market growth.
Advancements in Neurointerventional Procedures
Continuous innovation in minimally invasive neurointerventional procedures, such as thrombectomy and aneurysm repair, has enhanced the effectiveness and safety of treatments. Neuroprotection devices play a critical role in these procedures, boosting their clinical adoption and driving market expansion.
Rising Demand for Minimally Invasive and Safer Solutions
Patients and healthcare providers increasingly prefer minimally invasive, safer, and more effective solutions for managing neurological conditions. Neuroprotection devices that reduce procedural risks and improve patient outcomes are becoming central to this trend, boosting market demand.
Download the Neuroprotection Devices Market Report for In-Depth Insights on Pipeline and Forecast
What are the Latest Neuroprotection Devices Market Dynamics and Trends?
According to the British Heart Foundation (2025), approximately 640 million people worldwide were living with heart and circulatory diseases. Many medical procedures to treat these conditions carry the risk of embolization, where dislodged plaque or clots can travel to vital organs like the brain, causing stroke. Embolic Protection Devices (EPDs) play a critical role in capturing or deflecting this debris, reducing complications and improving patient outcomes.
Furthermore, neurovascular disorders such as ischemic stroke and transient ischemic attacks (TIAs) are becoming increasingly prevalent, putting patients at higher risk during endovascular or surgical interventions. Recent data from the British Heart Foundation (2024) reported that coronary (ischemic) heart disease affected around 200 million people globally, with approximately 110 million men and 80 million women impacted. Additionally, about 56 million women and 45 million men were stroke survivors, and an estimated 13 million people lived with congenital heart disease, with many more potentially undiagnosed.
According to the Parkinson’s Foundation (2022), more than 10 million people worldwide were living with Parkinson’s disease, a number that continues to rise. The growing number of patients undergoing treatments such as percutaneous coronary intervention (PCI) and carotid artery stenting has intensified the need for neuroprotection devices to prevent stroke and other neurological damage.
Neuroprotection Devices Market Segment Analysis
Neuroprotection Devices Market by Product Type
In the product type segment of the neuroprotection devices market, the cerebral embolic protection devices category is estimated to account for the largest market share in 2024. The growth of the cerebral neuroprotection devices (CEPDs) category is primarily driven by the rising prevalence of cardiovascular and neurovascular diseases, along with the various advantages these devices offer in neuroprotection.
CEPDs are designed to capture or deflect embolic debris generated during procedures such as transcatheter aortic valve replacement (TAVR), carotid artery stenting, and transcatheter valve repair. By preventing embolic debris from reaching the cerebral circulation, these devices significantly reduce the incidence of stroke and transient ischemic attacks (TIAs) immediately following such interventions.
Additionally, CEPDs allow for the collection of captured debris for pathological analysis, enhancing the understanding of embolic sources and informing future procedural strategies. Their versatility also enables use across a range of procedures, including saphenous vein graft interventions and certain neurovascular procedures, further expanding their clinical utility. CEPDs are particularly beneficial in complex anatomies and high-risk patients, offering enhanced safety and improving overall procedural outcomes, making them a preferred choice for many clinicians.
Moreover, ongoing product development and regulatory approvals are accelerating market growth. For instance, in June 2025, InspireMD announced CE Mark approval for its CGuard® Prime Embolic Prevention System (EPS) under the European Medical Device Regulation (MDR) for stroke prevention.
North America is Expected to Dominate the Overall Neuroprotection Devices Market
North America is expected to hold the largest share of the neuroprotection devices market in 2024, primarily due to the rising number of cardiovascular and neurovascular interventions. This dominance is further supported by strong clinical demand, advanced healthcare infrastructure, and significant investment in research and development.
According to recent data from the Centers for Disease Control and Prevention (2024), in 2022, approximately 4.9% of adults were diagnosed with coronary heart disease. Furthermore, by 2023, an estimated 12.1 million individuals in the United States were projected to have atrial fibrillation. Additionally, each year, over 795,000 people in the U.S. experience a stroke, with around 610,000 of these being first-time strokes.
According to the Parkinson’s Foundation (2022), approximately 90,000 individuals are diagnosed with Parkinson’s disease each year in the United States. The number of people affected by PD was expected to reach 1.2 million by 2030. According to data from the Population Reference Bureau published in January 2024, there were approximately 58 million individuals aged 65 and older in the United States in 2022, a number projected to rise to 82 million by 2050.
Rising product development activities by key companies are expected to further drive market growth. For instance, in October 2024, Contego Medical announced that it received FDA premarket approval (PMA) for the Neuroguard IEP® System, which features the company’s clinically-proven Integrated Embolic Protection™ (IEP) technology.
Recent Developmental Activities in the Neuroprotection Devices Market
- In May 2025, Terumo Interventional Systems announced the commercial launch of its FDA-approved ROADSAVER™ Carotid Stent System. Designed for use with the Nanoparasol® Embolic Protection System, the ROADSAVER Stent System is intended to treat carotid artery stenosis in patients at elevated risk of complications from carotid endarterectomy.
- In June 2025, InspireMD announced CE Mark approval for its CGuard® Prime Embolic Prevention System (EPS) under the European Medical Device Regulation (MDR) for stroke prevention.
- In October 2024, Contego Medical announced that it received FDA premarket approval (PMA) for the Neuroguard IEP® System, featuring the company’s clinically-proven Integrated Embolic Protection™ (IEP) technology.
Get Detailed Insights on the Neuroprotection Devices Market – Download the Full Report
Conclusion
The Neuroprotection Devices Market is poised for meaningful and sustained growth through 2032, driven by the rising global burden of cardiovascular and neurovascular disorders, a rapidly expanding aging population, and continuous advancements in minimally invasive interventional technologies. Cerebral embolic protection devices continue to dominate the product landscape, underpinned by their critical role in reducing stroke risk during complex procedures. North America remains the largest market, supported by advanced healthcare infrastructure and ongoing product development by leading industry players. With a projected CAGR of 6.87% from 2025 to 2032, the neuroprotection devices market presents significant opportunities for stakeholders, as innovation and regulatory momentum continue to accelerate the adoption of next-generation neuroprotective solutions across global healthcare settings.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail: abhishek@delveinsight.com
